Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 9, 2000 - Issue 8
Submit an article Journal homepage
74
Views
24
CrossRef citations to date
0
Altmetric
Review

Substance P antagonists: novel agents in the treatment of depression

Spilios V Argyropoulos Psychopharmacology Unit, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK. [email protected]
&
David J Nutt Psychopharmacology Unit, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK. [email protected]
Pages 1871-1875 | Published online: 24 Feb 2005

Bibliography

  • KRAMER MS, CUTLER NR, FEIGHNER J et al.: Distinctmechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281:1640–1645.
  • •The first and only positive study of a SP antagonist in depression.
  • HOKFELT TGM, CASTEL M-N, MORINO P, ZHANG X,DAGERLIND A: General overview of neuropeptides. In: Psychopharmacology. The fourth generation of progress. Bloom FE, Kupfer DJ (Eds.), Raven Press, New York, USA (1995)483–492.
  • •Useful general overview of the neuropeptide field.
  • WAHLESTEDT C: Reward for persistence in substance P research. Science (1998) 281:1624–1625.
  • SARIA A: The tachykinin NKi receptor in the brain: pharmacology and putative functions. Eur. J. Pharmacol. (1999) 375: 51–60.
  • •Useful review of the NKI receptor.
  • PENNEY JB JR.: Neurochemical neuroanatomy. In: Neuropsychiatty. Fogel BS, Schiffer RB, Rao SM (Eds.), Williams & Wilkins, Baltimore, USA (1996):145–171.
  • OTSUKA M, YOSHIOKA K: Neurotransmitter functions of mammalian tachykinins. PhysioL Rev. (1993) 73:229–308.
  • RUPNIAK NM, KRAMER MS: Discovery of the antidepres-sant and anti-emetic efficacy of substance P receptor (NKi) antagonists. Trends Pharmacol. Sci. (1999) 20:485–490.
  • •Conceptual review of developments in SP research from two of the pioneers in the field.
  • BARKER R: Substance P and neurodegenerative disorders: a speculative review. Neuropeptides (1991) 20 :73–78.
  • BARKER R, LARNER A: Substance P and multiple sclerosis. Med. Hypotheses (1992) 37:40–43.
  • MAGGI CA, PATACCHINI R, ROVERO P, GIACHETTI A: Tachykinin receptors and receptor antagonists. J Auton. Pharmacol. (1993) 13:958–962.
  • REGOLI D, BOUDON A, FAUCHERE J: Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. (1994) 46:551–599.
  • QUARTARA L, MAGGI CA: The tachykinin NKi receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides (1997) 31:537–563.
  • •Thorough review of Nici ligands.
  • IYENGAR S, HIPSKIND PA, GEHLERT DR et al.: LY303870, a centrally active neurokinin-1 antagonist with a long duration of action. J. Pharmacol. Exp. Ther. (1997) 280:774–785.
  • HOSOKI R, YANAGISAWA M, ONISHI Y, YOSHIOKA K, OTSUKA M: Pharmacological profiles of new orally active nonpep tide tachykinin NKi receptor antago-nists. Eur.J. Pharmacol. (1998) 341:235–241.
  • WALPOLE CSJ, BROWN MCS, JAMES IF et al.: Compara-tive, general pharmacology of SDZ NKT 343, a novel, selective NKi receptor antagonist. Br. J Pharmacol (1998) 124:83–92.
  • NAVARI RM, REINHARDT RR, GRALLA RJ et al.: Reduction of cisplastin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl. J. Med. (1999) 340:190–195.
  • BERRETTINI WH, RUBINOW PR, NURNBERGER JI, SIMMONS-ALLING S, POST RM, GERSHON ES: CSF substance P immunoreactivity in affective disorders. Psychiat. (1985) 20:965–968.
  • NUTT DJ: Substance P antagonists: a new treatment for depression? Lancet (1998) 352: 1644-1646.
  • •Discussion of the future directions in SP filed in depression and anxiety.
  • EDITORIAL: Delay for Merck's substance P blocker in depression. SCRIPT (1999) 2406:20.
  • BAKER KG, HALLIDAY GM, HORNUNG J-P, GEFFEN LB, COTTON RG, TORK I: Distribution, morphology and number of monoamine-synthetising and substance P containing neurons in the human dorsal raphe nucleus. Neuroscience (1991) 42:757–775.
  • SERGEYEV V, HOKFELT T, HURD Y: Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. NeuroRep. (1999) 10: 3967–3970.
  • •Review and important new evidence for the co-localisation of SP and 5-HT.
  • ARGYROPOULOS SV, NUTT DJ: Anhedonia and chronic mild stress model of depression. Psychopharmacol (1997) 134:333–336.
  • MURRAY CJL, LOPEZ AD: Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet (1997) 349:1498–1504.
  • FULLER RW: Mechanisms and functions of serotonin neuronal systems. Ann. NY Acad. Sci. (1996) 780:176–184.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.